Company news
Probiotix Health Plc (AQUIS:PBX) news
Every Probiotix Health Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Unaudited Interim Results to 30 June 2026
August 6, 2026
New Partnership Agreement in Belgium
July 23, 2026
New Partnership Agreement in Slovakia
June 1, 2026
New Strategic Alliance in Spain and Portugal
May 26, 2026
Final Results and Investor Presentation
March 30, 2026
Notice of Results and Investor Presentation
March 16, 2026
PDMR Shareholding
February 17, 2026
Statement re Share Price Movement
February 16, 2026
Holding(s) in Company
February 5, 2026
Director/PDMR Shareholding
February 4, 2026
Trading Update
January 21, 2026
Move from Access to Apex Segment of Aquis
November 3, 2025
Appointment of Aquis Corporate Adviser
October 23, 2025
New Commercial Partnership in Australia
October 20, 2025
New Commercial Partnership in Sweden
October 14, 2025
Q3 2025 Trading Update and Grant of Options
October 13, 2025
Unaudited Interim Results to 30 June 2025
September 8, 2025
Trading Update and Notice of Results
July 15, 2025
Result of AGM and Notice of Trading Update
June 27, 2025
Notice of Annual General Meeting - Clarification
June 5, 2025
Notice of AGM
May 30, 2025
Final Results
May 29, 2025
New Partnership Agreement in South Korea
March 28, 2025
Grant of Options
February 20, 2025
Result of Requisitioned General Meeting
November 1, 2024
Requisition update
October 30, 2024
Response to Publication of Circular by ProBiotix
October 18, 2024
Publication of Circular and Notice of GM
October 15, 2024
New Commercial Partnership in Mexico
October 10, 2024
Q3 2024 Trading Update
October 8, 2024
Appointment of Non-Executive Director
October 7, 2024
New Commercial Partnership in Ukraine
October 3, 2024
Total Voting Rights
September 30, 2024
Response to General Meeting Requisition
September 25, 2024
New Commercial Partnership in Greece
September 16, 2024
Response to OptiBiotix Health plc announcement
September 6, 2024
Share Subscription and Proposed Board Appointment
September 4, 2024
Half-year Report
August 30, 2024
New commercial partnership agreement in China
August 15, 2024
Result of AGM
August 8, 2024
New appointment
July 29, 2024
Six month trading update
July 15, 2024
Partner agreement with SymbioPharm
February 26, 2024
Change of auditor
February 9, 2024
Directorate Change
January 11, 2024
Distribution agreement
August 1, 2023
Commercial and scientific update
January 4, 2023
Unaudited Results to 30 June 2022
September 28, 2022
New commercialisation partner in Asia Pacific
September 14, 2022
Appointment of Chief Executive Officer
June 14, 2022